Cova. you, Thank
or from our Bentrio evaluating we patients month exciting patients or Bentrio To and a were clinical the X:X to for study per day efficacy of nasal vertigo. rhinitis, controlled the who XXX seasonal the a either spray the assets, as AM-XXX in Bentrio for times May, of ratio In in discuss at findings our via saline let's weeks needed. legacy nasal Now spray two nasal shared betahistine with self-administration trial there's SAR. receive enrolled trial, spray Bentrio, allergic drug-free nasal randomized short NASAR spray NASAR randomized Australia, X
is total level hours of within least period. subsequent care which treatment referring a over have rTNSS had out and endpoint drug-free reflective difference a worst X efficacy Bentrio average one-week sneezing, saline spray, nasal over congestion, rhinitis the of which nasal For defined the management. and points to the current when nasal past itching nose, eligibility, the rTNSS of XX of between run-in it rhinorrhea, standard to nasal patients symptom The allergic period in is baseline averaged the XX, score, treatment-free as was to at primary comes runny two-week the
relevant rate demonstrated The X.X statistically fold nasal or X.XX Bentrio-treated which of XX% than for from the significant and saline improvement X.X treatment highly participants saline. in results in the users. points rTNSS, outcomes over larger X.X XX% important or improvement compared was points. efficacy of clinical very in points above NASAR baseline spray. of saline study Bentrio The efficacy a just is good to was came Both spray good difference minimal well clinically
them prevents a Whereas spray those rinse-out which forms mucociliary and Bentrio thin particles a aims layer, helps natural of nasal remove to protective contact with mucosa the clearance. to through nasal saline articles, allergen
only for As already protective and where present within effects. exert the nasal distribution within about stays for less contrast, provides hour hours demonstrated coverage in X.X cavity. X its about Bentrio and narrow can a previous saline In cavity trial, the it sprays
release We to the in exposed demonstrated mites and house already extended efficacy expect in NASAR trials Bentrio for the trial and to grass further safety, hours residence a clinical the allergic controlled readout development data human medical to patients more submit The NASAR pollen in peer-reviewed conditions publication X results from shortly the or program Previous completes of journal. than Bentrio nasal the time tolerability rhinitis. and trial under article from in of volunteers. dust an
the nasal sprays. that to of with based similar of sprays, the observed reduction effectively to The common and issues, such that without of help in drug-free The Bentrio suggests medicated was formulation on use symptoms rhinitis. most the but accumulated data a frequently can symptoms experienced response preservative-free allergic tolerability to reduce
allow Sweden, we Scandinavian and Denmark July, the subject XXXX for agreement the the Nordic to with in to countries. later The Norway, of Nordic and first Pharma market of announced quarter beginning and will on. and and also marketing certain in milestones Pharma Norway exclusive collaboration In commercialize Bentrio in Bentrio for meeting agreement potentially an distribution in Finland
in look leading and partnering distribution to with for Bentrio time. key previously U.S. the this suspend to Europe, building Bentrio other context move its at and into to of management allergic Scandinavia. as decision and ongoing the and continued forward the rhinitis still and marketing partners Nordic brands with preparations have discussions, forward of markets We minimize own potential we communicated. are for in the U.S. marketing the have these activities made for Pharma together In sales on one in Discussions launching
$X burden help non-medicated the U.S. a that partners, over are as and option opportunity counter XXXX, close with It's and marketing preservative-free Bentrio to the this worth category. we allergic our the and forward to are to to in distribution looking with sales a making an comfort treatment rhinitis. daily remedies treatment deal noting major patients allergy safe estimated representing effective of Together reach available associated billion, with in
following the treatment of a most AM-XXX, AM-XXX been may has proceed proposed received may program. the our June to II This IND FDA benign is in was BPPV, development later. study IND a which a XX, our that of regards been the has from clearance clinical for major on the trial With in means vertigo, application Phase step review be the AM-XXX vertigo of paroxysmal common positional U.S. our conducted authorized in form and The
utility is clinical designed patients earlier also conducted An week and of in was BPPV. Phase treatment inner to the demonstrate well in AM-XXX clinical regain faster. balance new tolerability with a vertigo trial Phase that The in tumor TRAVERS AM-XXX's compensation, four following tolerated behind vestibular patients trial and II in II surgical ear trial the Europe, to recover course a demonstrated helped removal to enabling accelerate
previously announced, partner we for strategic to of further to our number health issues based mentioning vertigo divest initiated discussions delivery. we that and or intend RNA the structured pivot on this the program among the end, have general a partners AM-XXX in commercialization the probably most As balance context potential and worth development with in problems frequent approach. population. is It increasing are of a To
great in form XXXX. million standard in XX.X XX.X Betahistine, balance XX.X% the a AM-XXX XX.X% a in care believe problem of AM-XXX, is active We that the in adults substance worldwide, year to of XXXX, markets, vertigo countries betahistine with compared In the million both than oral reported treatment for or past or better much but also dozens U.S. marketed the in of bioavailability which tablets offers it's in not particular potential, but in existing betahistine in U.S.
CHFX.X Turning partnering of for the highlights anticipation were importantly, activities transaction million half of Revenues more to a the compared to CHFX.X next the for XXXX strategic SARS-CoV-X key aforementioned first the first XXXX, to commercial in our half reduce temporarily half financial of XXXX. and for waning for of Bentrio the markets. first decision infections reflecting around of million
for primarily for as the operating CHFX.X of six of expenditures XXXX, reduction was by marketing the activities research and The months six development and with trials lower were compared CHFX.X down loss months as first was of for Total million million commercial first a driven XXXX for sales and clinical XX.X%. went improvement reduced.
Financial in costs XXXX the projects with increased higher XXXX CHFX.X market compared related of outweighed million The end slightly from at the to at to same CHFX.X a million of million expenses administrative admin of half reductions first XX. the June and of deficit expenditures. decreased from equity CHFX.X capital was XXXX. loss General CHFX.X million. million time liabilities CHFX.X the improved XXXX first of in half as of for to net for CHFX.X at Shareholders' million a the deficit first half
warrants raised through $X the public XX, June we 'XX, of In equivalents million XXXX. July and XXXX, $X.XX December of in same cash duration. the five totaled of million net XX.X on with with price million. each prefunded offering proceeds and year compared warrants an XX, Cash CHFXX,XXX a number early or CHFX.X at CHFXX,XXX at of CHFX.X exercise equity on transaction The shares common yielded
of As the a CHFXX XX months range the our CHFXX the be million expect cash in of financial CHFXX statements issuance and result, date be to of recent million, in million from in CHFXX to we XXXX to need here the million. in total range to most
answering today. us would turn for questions I submitted to like that were the now to to
